Granulomatosis with Polyangiitis clinical trials at University of California Health
2 research studies open to eligible people
Iptacopan in Patients With ANCA Associated Vasculitis
open to eligible people ages 18-100
The purpose of this study is to evaluate the efficacy and safety of iptacopan compared to standard of care (SOC) to induce and maintain remission in study participants with active granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA), when used in combination with rituximab (RTX) induction. The trial will also assess the impact of iptacopan on disease relapses, evolution of renal function and proteinuria, GC side effects, patients' immune status, and QoL.
at UCLA
Longitudinal Study for Eosinophilic Granulomatosis With Polyangiitis
open to all eligible people
Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare immune system disorder that causes asthma, an excessive number of eosinophils (a type of white blood cell) in the blood, and the inflammation of blood vessels, or vasculitis. In order to properly treat EGPA, it is critical that the level of disease activity can be determined over the course of the disease. The purpose of this study is to determine new biological markers, or biomarkers, that may be used to assess the severity of this disease in people with EGPA.
at UCSD
Our lead scientists for Granulomatosis with Polyangiitis research studies include Niloofar Nobakht, MD.
Last updated: